% 0期刊文章% Roffel, Mirjam p % Boudewijn,伊尔丝m . %一辆面包车Nijnatten乔斯l %的费,阿伦% Vermeulen, Corneel j . %一辆面包车Oosterhout Antoon说道j . %阿弗莱克,凯伦%华,维姆·%马克,肯·r·%梅斯,塔尼亚% Heijink,艾琳·h·% Brandsma, van den Berge Corry-Anke %,microRNA (miRNA)表达的改变可以促进许多疾病的发病，包括哮喘。我们旨在识别在哮喘患者和健康对照组之间差异表达的mirna，并探索它们与哮喘的临床和炎症参数的关系。利用线性回归模型，对79例哮喘患者和82例健康对照者的支气管活检进行小RNA测序，确定差异表达的mirna。差异表达的mirna与临床和炎症性哮喘特征相关。利用相同支气管活检获得的mRNA数据分析了潜在的miRNA-mRNA相互作用，并用richr和g:Profiler鉴定了通路的富集。与对照组相比，在哮喘患者的支气管活检中共鉴定出78个差异表达的mirna，其中60个在吸烟和吸入皮质类固醇治疗后仍保持差异表达。基于miR-125b-5p与多种哮喘临床和炎症特征的显著相关性以及它们与哮喘相关基因的负相关性，我们鉴定了几种哮喘相关的miRNAs，包括miR-125b-5p和miR-223-3p。miR-125b-5p和miR-223-3p影响的最丰富的生物学途径是炎症反应和纤毛组装和组织。有趣的是，我们在血液、痰液和支气管活检中发现，miR-26a-5p的低表达与更严重的嗜酸性炎症有关。总的来说，我们确定了miR-125b-5p、miR-223-3p和miR-26a-5p作为可能参与哮喘发病机制的潜在调控因子。脚注本手稿最近已被接受发表在欧洲呼吸杂志。 It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Roffel has nothing to disclose.Conflict of interest: Dr. Boudewijn has nothing to disclose.Conflict of interest: Dr. van Nijnatten has nothing to disclose.Conflict of interest: Dr. Faiz has nothing to disclose.Conflict of interest: Dr. Vermeulen has nothing to disclose.Conflict of interest: Dr. Van Oosterhout reports and Van Oosterhout owns GSK shares.Conflict of interest: Dr. Affleck reports and I am an employee of GlaxoSmithKline but have no conflict of interest related to this manuscript.Conflict of interest: Dr. Timens reports personal fees from Roche Diagnostics/Ventana, personal fees from Merck Sharp Dohme, personal fees from Bristol-Myers-Squibb, personal fees from Diaceutics, outside the submitted work.Conflict of interest: Dr. Bracke has nothing to disclose.Conflict of interest: Dr. Maes reports grants from Ghent University, grants from Fund for Scientific Research in Flanders, during the conduct of the study; personal fees from GlaxoSmithKline, grants from Chiesi, outside the submitted work; and is shareholder from Oryzon Genomics and Mendelion Lifesciences SL.Conflict of interest: Dr. Heijink has nothing to disclose.Conflict of interest: Dr. Brandsma has nothing to disclose.Conflict of interest: Dr. van den Berge reports research grants to Institution from GlaxoSmithKline. Sanofi, Novartis, Genentech, Roche, outside the submitted work. %U //www.qdcxjkg.com/content/erj/early/2021/07/29/13993003.01294-2021.full.pdf